Study finds old brains still make neurons

https://www.nature.com/articles/s41591-019-0375-9 Reports of old brains’ decrepitude have been greatly exaggerated, scientists reported on Monday, unveiling results that contradict a much-discussed 2018 study and instead support the idea that human gray matter is capable of generating new neurons up to the ninth decade of life. The research, published in Nature Medicine, also found that old brains from

Read More


A special edition of The American Statistician presents over 40 papers on “Statistical inference in the 21st century: a world beyond P < 0.05”

Statistical significance has become an infallible doctrine of scientific research. However, many scientists and statisticians argue that long-held beliefs about statistical significance have, in fact, harmed the scientific community. In hypothesis testing, the p-value gives the probability or likelihood that the null hypothesis is true and is frequently used as a measure of “statistical significance.”

Read More


Hope for people with FOP disease as three drugs enter clinical trial – and one could be approved by next year

Fibrodysplasia ossificans progressiva (FOP) is a rare, genetic disease in which damaged muscle and soft tissue turn into bone It affects just 800 people worldwide and there is currently no known cure   Three drugs have entered clinical trials as potential treatments for the condition They target the genes and proteins responsible for the hyperactive bone growth

Read More


Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality

Question  Is consuming dietary cholesterol or eggs associated with incident cardiovascular disease (CVD) and all-cause mortality? Findings  Among 29 615 adults pooled from 6 prospective cohort studies in the United States with a median follow-up of 17.5 years, each additional 300 mg of dietary cholesterol consumed per day was significantly associated with higher risk of incident CVD (adjusted

Read More


US FDA approves the first immunotherapy for extensive-stage small cell lung cancer

Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) First new initial treatment option approved by the U.S. Food and Drug Administration (FDA) for people with ES-SCLC in more than 20 years Tecentriq in combination with chemotherapy

Read More